Cargando…

2404. Telavancin (TLV) and Vancomycin (VAN) Activity and Impact on Mechanical Properties When Incorporated into Orthopedic Bone Cement

BACKGROUND: To increase available antibiotics for local administration in total joint replacements, this study investigated TLV and VAN added to Palacos® bone cement. Mechanical properties and antimicrobial activity of eluted antibiotics on common causative orthopedic implant pathogens were assessed...

Descripción completa

Detalles Bibliográficos
Autores principales: Bishop, Aaron, Kim, Sunjung, Squire, Matthew, Ploeg, Heidi-Lynn, Rose, Warren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253403/
http://dx.doi.org/10.1093/ofid/ofy210.2057
_version_ 1783373486140424192
author Bishop, Aaron
Kim, Sunjung
Squire, Matthew
Ploeg, Heidi-Lynn
Rose, Warren
author_facet Bishop, Aaron
Kim, Sunjung
Squire, Matthew
Ploeg, Heidi-Lynn
Rose, Warren
author_sort Bishop, Aaron
collection PubMed
description BACKGROUND: To increase available antibiotics for local administration in total joint replacements, this study investigated TLV and VAN added to Palacos® bone cement. Mechanical properties and antimicrobial activity of eluted antibiotics on common causative orthopedic implant pathogens were assessed. METHODS: Palacos (40 g package) samples were loaded with TLV or VAN powder (control 2.0 g) to test drug activity and mechanical properties: bending, compression, and fracture toughness. Samples were prepared following clinical standards and as previously described (Slane et al., 2014 MSE 42: 168–176). All mechanical samples were wet cured for 21 days in PBS at 21(o)C before testing in accordance with ISO 5833. With a starting inoculum of 10(3) CFU/mL, antibiotic activity was measured for 14 days against: two methicillin-resistant S. aureus, one methicillin-susceptible S. aureus and one S. epidermidis. RESULTS: The eluted dosages from samples with 0.25 g VAN or more per Palacos package were sufficient to eliminate a 10(3) CFU/mL inoculum of S. aureus organisms. 2.0 g of TLV was required to achieve the same bactericidal effect. TLV 2.0 g was able to fully clear the initial inoculum of a high biofilm producing S. epidermidis. No tested vancomycin dosage replicated these results. Adding more than 0.5 g of TLV or VAN per Palacos package reduced compressive yield strength to (VAN) or below (TLV) the ISO 70MPa minimum. Fracture toughness and flexural strength were not significantly altered with either antibiotic. CONCLUSION: Adding either TLV or VAN to Palacos before polymerization reduced bending properties similarly but maintained ISO standards. More VAN than TLV can be added and still maintain compressive yield strength above ISO requirements (1.0 g VAN vs. 0.5 g TLV). VAN eliminated the tested S. aureus strains at a lower added mass. However, TLV was more effective against a high biofilm producing S. epidermidis. VAN was highly effective at eliminating a bacterial inoculum consistent with surgical contamination while maintaining ISO standards. The authors would like to acknowledge Theravance Biopharma US, Inc. for their support and funding. DISCLOSURES: A. Bishop, Theravance: Investigator, Educational support, Research support and Salary. S. Kim, Theravance: Investigator, Research grant and Research support. W. Rose, Theravance: Consultant and Grant Investigator, Consulting fee and Research grant.
format Online
Article
Text
id pubmed-6253403
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62534032018-11-28 2404. Telavancin (TLV) and Vancomycin (VAN) Activity and Impact on Mechanical Properties When Incorporated into Orthopedic Bone Cement Bishop, Aaron Kim, Sunjung Squire, Matthew Ploeg, Heidi-Lynn Rose, Warren Open Forum Infect Dis Abstracts BACKGROUND: To increase available antibiotics for local administration in total joint replacements, this study investigated TLV and VAN added to Palacos® bone cement. Mechanical properties and antimicrobial activity of eluted antibiotics on common causative orthopedic implant pathogens were assessed. METHODS: Palacos (40 g package) samples were loaded with TLV or VAN powder (control 2.0 g) to test drug activity and mechanical properties: bending, compression, and fracture toughness. Samples were prepared following clinical standards and as previously described (Slane et al., 2014 MSE 42: 168–176). All mechanical samples were wet cured for 21 days in PBS at 21(o)C before testing in accordance with ISO 5833. With a starting inoculum of 10(3) CFU/mL, antibiotic activity was measured for 14 days against: two methicillin-resistant S. aureus, one methicillin-susceptible S. aureus and one S. epidermidis. RESULTS: The eluted dosages from samples with 0.25 g VAN or more per Palacos package were sufficient to eliminate a 10(3) CFU/mL inoculum of S. aureus organisms. 2.0 g of TLV was required to achieve the same bactericidal effect. TLV 2.0 g was able to fully clear the initial inoculum of a high biofilm producing S. epidermidis. No tested vancomycin dosage replicated these results. Adding more than 0.5 g of TLV or VAN per Palacos package reduced compressive yield strength to (VAN) or below (TLV) the ISO 70MPa minimum. Fracture toughness and flexural strength were not significantly altered with either antibiotic. CONCLUSION: Adding either TLV or VAN to Palacos before polymerization reduced bending properties similarly but maintained ISO standards. More VAN than TLV can be added and still maintain compressive yield strength above ISO requirements (1.0 g VAN vs. 0.5 g TLV). VAN eliminated the tested S. aureus strains at a lower added mass. However, TLV was more effective against a high biofilm producing S. epidermidis. VAN was highly effective at eliminating a bacterial inoculum consistent with surgical contamination while maintaining ISO standards. The authors would like to acknowledge Theravance Biopharma US, Inc. for their support and funding. DISCLOSURES: A. Bishop, Theravance: Investigator, Educational support, Research support and Salary. S. Kim, Theravance: Investigator, Research grant and Research support. W. Rose, Theravance: Consultant and Grant Investigator, Consulting fee and Research grant. Oxford University Press 2018-11-26 /pmc/articles/PMC6253403/ http://dx.doi.org/10.1093/ofid/ofy210.2057 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Bishop, Aaron
Kim, Sunjung
Squire, Matthew
Ploeg, Heidi-Lynn
Rose, Warren
2404. Telavancin (TLV) and Vancomycin (VAN) Activity and Impact on Mechanical Properties When Incorporated into Orthopedic Bone Cement
title 2404. Telavancin (TLV) and Vancomycin (VAN) Activity and Impact on Mechanical Properties When Incorporated into Orthopedic Bone Cement
title_full 2404. Telavancin (TLV) and Vancomycin (VAN) Activity and Impact on Mechanical Properties When Incorporated into Orthopedic Bone Cement
title_fullStr 2404. Telavancin (TLV) and Vancomycin (VAN) Activity and Impact on Mechanical Properties When Incorporated into Orthopedic Bone Cement
title_full_unstemmed 2404. Telavancin (TLV) and Vancomycin (VAN) Activity and Impact on Mechanical Properties When Incorporated into Orthopedic Bone Cement
title_short 2404. Telavancin (TLV) and Vancomycin (VAN) Activity and Impact on Mechanical Properties When Incorporated into Orthopedic Bone Cement
title_sort 2404. telavancin (tlv) and vancomycin (van) activity and impact on mechanical properties when incorporated into orthopedic bone cement
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253403/
http://dx.doi.org/10.1093/ofid/ofy210.2057
work_keys_str_mv AT bishopaaron 2404telavancintlvandvancomycinvanactivityandimpactonmechanicalpropertieswhenincorporatedintoorthopedicbonecement
AT kimsunjung 2404telavancintlvandvancomycinvanactivityandimpactonmechanicalpropertieswhenincorporatedintoorthopedicbonecement
AT squirematthew 2404telavancintlvandvancomycinvanactivityandimpactonmechanicalpropertieswhenincorporatedintoorthopedicbonecement
AT ploegheidilynn 2404telavancintlvandvancomycinvanactivityandimpactonmechanicalpropertieswhenincorporatedintoorthopedicbonecement
AT rosewarren 2404telavancintlvandvancomycinvanactivityandimpactonmechanicalpropertieswhenincorporatedintoorthopedicbonecement